LGND Ligand Corp: יחס שווי פעילות לרווח לפני ריבית, מסים ופחת
Ligand Pharmaceuticals (LGND) generates royalty revenue by integrating the Captisol system into the formulas of industry behemoths. Data from GURU.Markets is used for this EV/EBITDA enterprise value multiple chart, where the metric level stands at 92.70. The company is modernizing its centers to meet ESG standards by utilizing waste. However, a heavy reliance on external contractors forces management to regularly update its pool of manufacturing partners.
פילוחי מדדים מקיפים ואנליטיקה עבור Ligand Pharmaceuticals Incorporated (LGND)
The EV/EBITDA multiple determines the business value relative to its operating profit before depreciation, taxes, and interest, allowing for an assessment of cash flow generation efficiency regardless of capital structure. By analyzing changes in the EV/EBITDA level of Ligand Pharmaceuticals (LGND), an investor can observe the asset's stability, as the pharmaceutical business's royalty model minimizes the impact of economic cycles and macro shocks on market value.
